+25.2%
CVNA vs MRNA
+945.0%
-919.8%
-41.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +8.8% | +13.1% | -4.3% | +8.0% |
| 7D | +31.3% | +20.6% | +10.7% | +29.9% |
| 30D | +21.7% | +27.1% | -5.4% | +19.8% |
| 3M | +14.0% | +353.4% | -339.4% | -0.7% |
| 6M | +3.0% | +446.3% | -443.3% | -13.6% |
| YTD | -8.1% | +776.2% | -784.3% | -26.8% |
| 1Y | +25.2% | +987.9% | -962.7% | -6.7% |
| All | +25.2% | +945.0% | -919.8% | -6.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling